B and T Cell-Mediated Autoimmune Disease Drug Development Summit

Memo

Join this community of pioneers and 32+ expert speakers to aid discovery, development, optimization and strategy for a new generation of treatment within this area of vastly unmet clinical need at the 2nd edition of the B and T Cell-Mediated Autoimmune Disease Drug Development Summit. This cross-disciplinary program featuring keynote talks from clinical decision-makers in large pharma, biotech and academia, will give you insight into the full therapeutic opportunity of drug candidates against various plasma, B and T cell targets. Unite with other B and T cell researchers as we look to optimize therapeutic targeting of the bidirectional interactions between B and T cells, B cell functions (autoantibody production, antigen presentation, T cell help and cytokine production) and autoreactive T cells contribution to autoimmune pathogenesis and disease progression. View our full event guide to see our complete speaker line-up, latest agenda and workshop details. https://b-and-t-cell-for-autoimmune.com/full-event-guide Date and Time: On Tuesday October 05, 2021 at 7:30 am (ends Thursday October 07, 2021 at 5:40 pm) Prices: Conference + 1 Workshop - Industry Pricing - Early Bird (save $700): USD 1798.00,Conference Only - Industry Pricing - Early Bird (save $500): USD 1599.00,Conference + 1 Workshop - Academic - Early Bird (Save $650): USD 1548.00,Conference Only - Academic - Early Bird (Save $500): USD 1399.00 URLs: Brochure: https://go.evvnt.com/795075-0?pid=5569 Tickets: https://go.evvnt.com/795075-3?pid=5569 Speakers: Dhavalkumar Patel Executive Vice President and Chief Scientific Officer UCB, Roland Grenningloh Senior Director EMD Serono, Ruxandra Sîrbulescu Instructor in Medicine, Vaccine and Immunotherapy Center Massachusetts General Hospital, Harvard Medical School, Ryan Roundtree Senior Director, Preclinical Pharmacology Nurix Therapeutics, Simi Ahmed Senior Vice President, Strategic Partnerships NYSCF, Vibha Jawa Executive Director Bristol-Myers Squibb, Bob Axtell Associate Member Arthritis and Clinical Immunology Division Oklahoma Medical Research Foundation, Evelyn Peelen Senior Scientist Immunic AG, Jacquelyn Brown Manager, Medical Affairs Provention Bio, Kea Martin Scientist (R&D) Polyneuron Pharmaceuticals, Lynne Murray Senior Vice President - Research and Development MiroBio, Rab Prinjha Vice President, Head of Adaptive Immunity and Immuno-Epigenetics Research Unit GlaxoSmithKline, David Alleva VP, Immunology IM Therapeutics, Evelien Schurgers Research Team Leader Apitope, Natalia Giltiay Affiliate Assistant Professor University of Washington and Staff Scientist, Immunology Group, Kyverna Therapeutics, Nate Murray Global PRA Advisor – Autoimmune Eli Lilly and Co., Sally Ward Professor - Molecular Immunology and Director - Translational Immunology University of Southampton, Srini Ramanathan Group Vice President, Development Sciences and Site Head Horizon Therapeutics, James Rush Global New Products Director Novartis, Jan Terje Andersen Prof. Biomedical Innovation and Group Leader, Department of Immunology University of Oslo and Oslo University Hospital, Marko Radic Associate Professor UTHSC, Michael Mingueneau Director, Research Biogen, Stephen Miller Professor of Microbiology, Immunology Northwestern University Feinberg School of Medicine, Stephen Wilson Global Head of Innovation Cytocom Therapeutics, Ana Correia Senior Global Clinical Research Scientist Eli Lilly and Co., Christopher VanDeusen Chief Scientific Officer Artax Biopharma, Judy Chou President and Chief Executive Officer AltruBio, Michael Palte Associate Medical Director, Clinical Development Biogen, Mike Handley Chief Executive Officer and Board Member Cytocom Therapeutics, Venkat Reddy Consultant Rheumatologist and Honorary Lecturer University College Hospital and University College London, David De Graaf President and Chief Executive Officer Abcuro, Thomas Tedder Alter Geller Professor for Research in Immunology Departments of Immunology and Pediatrics Duke University Medical Center